论文部分内容阅读
目的制备肝素化磁介孔硅纳米粒,并负载多柔比星,考察该载药系统的体外释药及抗癌活性。方法用相转移法和溶胶-凝胶法合成单分散核/壳结构的磁介孔硅纳米粒(MMSNs),以共价结合的方法合成肝素化磁介孔硅纳米粒,然后进行药物在肝素化磁介孔硅纳米粒上的负载与体外释放实验、肝素化磁介孔硅纳米粒的细胞摄入实验及肝素化磁介孔硅纳米粒负载多柔比星的体外细胞学实验。结果肝素化磁介孔硅纳米粒能够明显延缓多柔比星的释放,能够被肝癌细胞HepG2摄入、对HepG2细胞具有明显的杀伤作用、对碱性成纤维细胞生长因子诱导的HepG2细胞增殖具有明显的抑制作用。结论肝素化磁介孔硅纳米粒作为药物载体在传递抗肿瘤药物方面具有潜在的应用前景。
Objective To prepare heparinized magnetic mesoporous silica nanoparticles loaded with doxorubicin to investigate the in vitro drug release and anticancer activity of the drug-loaded system. Methods Monodisperse core / shell magnetic mesoporous silica nanoparticles (MMSNs) were synthesized by phase-transfer method and sol-gel method. Heparinized magnetic nanoparticle was synthesized by covalent bonding method. Loaded and in vitro release experiments on the magnetic nanoparticle, the cell uptake experiments of heparinized magnetic nanoparticle and the in vitro cytological experiment of heparinized magnetic nanoparticle loaded with doxorubicin. Results Heparinized magnetic mesoporous silica nanoparticles could significantly delay the release of doxorubicin, which could be taken up by HepG2 hepatoma cells and had a significant killing effect on HepG2 cells and proliferation of HepG2 cells induced by basic fibroblast growth factor Obvious inhibition. Conclusion Heparinized magnetic mesoporous silica nanoparticles as a drug carrier in the delivery of anti-tumor drugs has potential applications.